Clinical trials: Head Neck Cancer
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic…
- Trial name
- NCT04785820
- Testing
- Lomvastomig, Tobemstomig, Nivolumab
- Where
- 52 sites in Argentina, Brazil and 16 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma, Neoplasia
Optical Imaging of Head and Neck Cancer
This study examines if certain imaging techniques and devices can aid the surgeon in detecting cancer during the surgical procedure.
- Conditions
- Squamous Cell Carcinoma, Neoplasia, Head and Neck Cancer
- Trial name
- NCT01456143
- Testing
- High Resolution Microendoscopy (HRME), Proflavine hemisulfate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sharmila Anandasabapathy, MD
Parathyroid Adenomas
High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma
This study aims to determine whether HIFU treatment is a safe and effective alternative to an operation to remove all or part of the affected gland.
- Trial name
- NCT01291498
- Testing
- High Intensity Focused Ultrasound
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Oxford University Hospitals NHS Trust
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Olfactory Neuroblastoma, Esthesioneuroblastoma
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
Background: Olfactory neuroblastoma (ONB) is a rare cancer of the nasal cavity. At diagnosis, it is usually locally advanced. It tends to spread to the neck. Sometimes it spreads to the lungs and bones.
- Conditions
- Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
- Trial name
- NCT05012098
- Testing
- Bintrafusp alfa/M7824, Ibuprofen, PET scan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may…
- Trial name
- NCT00956007
- Testing
- cetuximab, intensity-modulated radiation therapy
- Where
- 264 sites in United States, Canada and 2 more
- Volunteers
- 702 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer, Head and Neck Cancer
A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation
Approximately 60 patients will be enrolled with highly suspected lung cancer, or head and neck cancer. The patients must also be starting radiotherapy or a chemoradiotherapy regimen (except with 5-fluorouracil).
- Trial name
- FLT101 (NCT00847509)
- Testing
- [F-18]FLT
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Siemens Molecular Imaging
Malignant Melanoma, Head and Neck Cancer
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more…
- Trial name
- NCT02331134
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
- Trial name
- NCT03602911
- Testing
- The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- West Virginia University
Squamous Cell Carcinoma of the Head and Neck
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
This trial examines survival and toxicity in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities…
- Trial name
- NCT01104922
- Testing
- Cetuximab, Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- David A. Clump, MD, PhD
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer
- Trial name
- NCT03405142
- Testing
- Panitumumab-IRDye800, Lymphoseek
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Eben Rosenthal
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal
- Trial name
- NCT03233724
- Testing
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thyroid Carcinoma, Radioactive Iodine Level
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
The purpose of this study is to explore whether administration of preservative free artificial tears will decrease the level of detectable radioiodine in the tears and nasolacrimal duct system of patients undergoing radioiodine…
- Trial name
- NCT04327999
- Testing
- Artificial Tears
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) 2.0
Head and neck cancer (HNC) survivors with body image-related distress (BID) will be randomized to 5-weeks of tablet-based BRIGHT or tablet-based active control (AC; electronic information about HNC recovery).
- Trial name
- BRIGHT (NCT03831100)
- Testing
- BRIGHT, Active Control
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Medical University of South Carolina
Oral Epithelial Dysplasia, Mild or Moderate Grade
Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral epithelial dysplasia (OED) is one of the common precancerous lesions among Chinese adults. Biomarker is not available for detection of malignant potential of OED till now.
- Trial name
- NCT00835341
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Peking University
Squamous Cell Carcinoma, Oral Cancer
Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
This is a Phase II study designed to test the efficacy of chemotherapy with docetaxel, cisplatinum (cisplatin) and 5-fluorouracil in patients with squamous cell carcinoma of the oral cavity to determine what effects these agents…
- Trial name
- NCT00400205
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Mouth Neoplasms, Head and Neck Neoplasms
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Background: Advanced-stage head and neck cancer (head and neck squamous cell carcinoma [HNSCC]) has moderately successful treatment outcomes, usually involving surgery as part of the standard treatment.
- Conditions
- Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
- Trial name
- NCT01195922
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Solid Tumors
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell…
- Trial name
- NCT03006887
- Testing
- lenvatinib, pembrolizumab
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Eisai Co., Ltd.
Head and Neck Neoplasms
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and…
- Trial name
- NCT03040999
- Testing
- Pembrolizumab, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 804 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.